A Myelodysplastic Syndrome Patient with Del(9Q) Cytogenetic Aberration: A Rare Case Report

Read full text Summarise with VIRAT
Authors: Budi Setiawan, Kevin Tandarto, Daniel Rizky, Damai Santosa, Eko Adhi Pangarsa, Catharina Suharti
Cited by: 0
References: 12

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract: Deletion of the long arm of chromosome 9 [del(9q)] is an exceptionally rare cytogenetic abnormality in myelodysplastic syndrome (MDS), more frequently described in acute myeloid leukemia. Due to the paucity of reported cases, the clinical behavior and optimal management of del(9q) MDS remain poorly defined. A 51-year-old Indonesian woman presented with transfusion-dependent anemia and thrombocytopenia. Bone marrow evaluation revealed dysplastic features consistent with MDS, and cytogenetic analysis demonstrated an isolated deletion of 9q [del(9)(q33–qter)]. The patient was treated with lenalidomide 10 mg daily on days 1–21 of a 28-day cycle. The treatment was well tolerated without major adverse effects or cytopenic complications during more than four years of follow-up. A sustained hematologic improvement was observed, characterized by progressive normalization of hemoglobin levels, stable leukocyte counts, and recovery of platelet counts. The patient achieved complete transfusion independence within several months and maintained clinical stability throughout the observation period. This case highlights the potential efficacy and tolerability of lenalidomide in MDS with isolated del(9q), suggesting that its therapeutic benefits may extend beyond the del(5q) subset.

Fields of Study & Subjects

Acute Myeloid Leukemia Research Retinoids in leukemia and cellular processes Hematopoietic Stem Cell Transplantation

Publication details

Journal / source
Journal of Applied Hematology
Volume
17
Issue
1
Pages
71–75
Publication date
1 January 2026
Language
EN